Prediction of Three-Year Mortality After Deceased Donor Kidney Transplantation in Adults with Pre-Transplant Donor and Recipient Variables.


Journal

Annals of transplantation
ISSN: 2329-0358
Titre abrégé: Ann Transplant
Pays: United States
ID NLM: 9802544

Informations de publication

Date de publication:
17 May 2019
Historique:
entrez: 18 5 2019
pubmed: 18 5 2019
medline: 24 12 2019
Statut: epublish

Résumé

BACKGROUND Prognostic models for 3-year mortality after kidney transplantation based on pre-transplant donor and recipient variables may avoid futility and thus improve donor organ allocation. MATERIAL AND METHODS There were 1546 consecutive deceased-donor kidney transplants in adults (January 1, 2000 to December 31, 2012) used to identify pre-transplant donor and recipient variables with significant independent influence on long-term survival (Cox regression modelling). Detected factors were used to develop a prognostic model for 3-year mortality in 1289 patients with follow-up of >3 years (multivariable logistic regression). The sensitivity and specificity of this model's prognostic ability was assessed with the area under the receiver operating characteristic curve (AUROC). RESULTS Highly immunized recipients [hazard ratio (HR: 2.579, 95% CI: 1.272-4.631], high urgency recipients (HR: 3.062, 95% CI: 1.294-6.082), recipients with diabetic nephropathy (HR: 3.471, 95% CI: 2.476-4.751), as well as 0, 1, or 2 HLA DR mismatches (HR: 1.349, 95% CI: 1.160-1.569) were independent and significant risk factors for patient survival. Younger recipient age ≤42.1 years (HR: 0.137, 95% CI: 0.090-0.203), recipient age 42.2-52.8 years (HR: 0.374, 95% CI: 0.278-0.498), recipient age 52.9-62.8 years (HR: 0.553, 95% CI: 0.421-0.723), short cold ischemic times ≤11.8 hours (HR: 0.602, 95% CI: 0.438-0.814) and cold ischemic times 11.9-15.3 hours (HR: 0.736, 95% CI: 0.557-0.962) reduced this risk independently and significantly. The AUROC of the derived model for 3-year post-transplant mortality with these variables was 0.748 (95% CI: 0.689-0.788). CONCLUSIONS Older, highly immunized or high urgency transplant candidates with anticipated longer cold ischemic times, who were transplanted with the indication of diabetic nephropathy should receive donor organs with no HLA DR mismatches to improve their mortality risk.

Identifiants

pubmed: 31097680
pii: 913217
doi: 10.12659/AOT.913217
pmc: PMC6540619
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

273-290

Références

Am J Transplant. 2003;3 Suppl 4:114-25
pubmed: 12694055
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Nephrol Dial Transplant. 2005 Jan;20(1):34-41
pubmed: 15522904
JAMA. 2005 Dec 7;294(21):2726-33
pubmed: 16333008
Transplantation. 1992 Jan;53(1):55-9
pubmed: 1733086
Am J Transplant. 2008 Jan;8(1):50-7
pubmed: 17973969
Nephrol Dial Transplant. 2010 Dec;25(12):4055-61
pubmed: 20558663
Curr Opin Organ Transplant. 2013 Apr;18(2):174-8
pubmed: 23337956
Clin Transplant. 2013 Jul-Aug;27(4):517-22
pubmed: 23731367
BMC Geriatr. 2013 Jul 24;13:79
pubmed: 23883109
Transpl Int. 2014 Jan;27(1):19-27
pubmed: 24138291
Transplantation. 2014 Feb 15;97(3):330-6
pubmed: 24202143
Transpl Int. 2014 Feb;27(2):219-25
pubmed: 24236869
J Negat Results Biomed. 2013 Dec 24;12:18
pubmed: 24365258
Transplant Res. 2014 Sep 24;3:18
pubmed: 25276347
J Am Geriatr Soc. 2014 Dec;62(12):2235-42
pubmed: 25439325
Prog Transplant. 2015 Mar;25(1):70-6
pubmed: 25758804
J Bras Nefrol. 2015 Apr-Jun;37(2):212-20
pubmed: 26154642
Transplantation. 2016 Feb;100(2):400-6
pubmed: 26516673
Transplantation. 2016 Oct;100(10):2160-7
pubmed: 26599492
Ann Transplant. 2016 Feb 11;21:94-104
pubmed: 26864516
Transplantation. 2017 Jun;101(6):1353-1364
pubmed: 27391198
Surg Oncol. 2017 Jun;26(2):178-187
pubmed: 28577724
Radiology. 1982 Apr;143(1):29-36
pubmed: 7063747

Auteurs

Ysabell Schwager (Y)

Core Facility Quality Management and Health Technology Assessment in Transplantation, Integrated Research and Treatment Facility Transplantation (IFB-Tx), Hannover Medical School, Hannover, Germany.

Simon Alexander Littbarski (SA)

Core Facility Quality Management and Health Technology Assessment in Transplantation, Integrated Research and Treatment Facility Transplantation (IFB-Tx), Hannover Medical School, Hannover, Germany.

Almut Nolte (A)

Core Facility Quality Management and Health Technology Assessment in Transplantation, Integrated Research and Treatment Facility Transplantation (IFB-Tx), Hannover Medical School, Hannover, Germany.

Alexander Kaltenborn (A)

Core Facility Quality Management and Health Technology Assessment in Transplantation, Integrated Research and Treatment Facility Transplantation (IFB-Tx), Hannover Medical School, Hannover, Germany.

Nikos Emmanouilidis (N)

Department of General, Visceral and Transplant Surgery, Hannover Medical School, Hannover, Germany.

Dennis Kleine-Döpke (D)

Department of General, Visceral and Transplant Surgery, Hannover Medical School, Hannover, Germany.

Jürgen Klempnauer (J)

Department of General, Visceral and Transplant Surgery, Hannover Medical School, Hannover, Germany.

Harald Schrem (H)

Core Facility Quality Management and Health Technology Assessment in Transplantation, Integrated Research and Treatment Facility Transplantation (IFB-Tx), Hannover Medical School, Hannover, Germany.
Department of General, Visceral and Transplant Surgery, Hannover Medical School, Hannover, Germany.
Department of General, Visceral and Transplant Surgery, Medical University of Graz, Graz, Austria.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH